REVX.F Stock Overview

Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. More details

REVX.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	5/6

Rewards

Trading at 33% below our estimate of its fair value

Earnings are forecast to grow 19.63% per year

Pays a reliable dividend of 1.57%

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Revenio Group Oyj Competitors

IRADIMED

NasdaqGM:IRMD

US$666.4m

InMode

NasdaqGS:INMD

US$956.9m

Semler Scientific

NasdaqCM:SMLR

US$310.3m

CONMED

NYSE:CNMD

US$1.5b

Price History & Performance

Summary of share price highs, lows and changes for Revenio Group Oyj
Historical stock prices
Current Share Price	€27.85
52 Week High	€38.89
52 Week Low	€27.85
Beta	1.44
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	2,260.17%

Recent updates

Shareholder Returns

	REVX.F	US Medical Equipment	US Market
7D	0%	-0.1%	1.8%
1Y	n/a	6.3%	9.5%

Return vs Industry: Insufficient data to determine how REVX.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how REVX.F performed against the US Market.

Price Volatility

Is REVX.F's price volatile compared to industry and market?
REVX.F volatility
REVX.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	4.1%

Stable Share Price: REVX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine REVX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	241	Jouni Toijala	www.reveniogroup.fi

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.

Revenio Group Oyj Fundamentals Summary

How do Revenio Group Oyj's earnings and revenue compare to its market cap?
REVX.F fundamental statistics
Market cap	US$741.97m
Earnings (TTM)	US$20.22m
Revenue (TTM)	US$113.47m

36.7x

P/E Ratio

6.5x

P/S Ratio

Is REVX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REVX.F income statement (TTM)
Revenue	€103.80m
Cost of Revenue	€30.60m
Gross Profit	€73.20m
Other Expenses	€54.70m
Earnings	€18.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)	0.70
Gross Margin	70.52%
Net Profit Margin	17.82%
Debt/Equity Ratio	10.3%

How did REVX.F perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

58%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/19 13:51
End of Day Share Price	2024/12/20 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revenio Group Oyj is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Pia Rosqvist-Heinsalmi	Carnegie Investment Bank AB
Daniel Lepisto	Danske Bank
null null	Evli Bank plc